<DOC>
	<DOCNO>NCT00301457</DOCNO>
	<brief_summary>The purpose study determine whether 6 year adjuvant anastrozole improve disease free survival compare 3 year adjuvant anastrozole postmenopausal hormone sensitive breast cancer patient , subsequent 2-3 year tamoxifen</brief_summary>
	<brief_title>Different Durations Adjuvant Anastrozole Therapy After 2 3 Years Tamoxifen Therapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>postmenopausal patient hormone receptor positive breast cancer already receive 2 3 year adjuvant tamoxifen , never sign locoregional recurrence distant metastasis Previous hormonal therapy adjuvant breast cancer treatment besides tamoxifen . Previous history invasive breast cancer within last 10 year , breast cancer currently treat tamoxifen</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hormone Sensitive Primary Breast Cancer</keyword>
	<keyword>Adjuvant Treatment</keyword>
	<keyword>Aromatase Inhibitor</keyword>
</DOC>